4 Companies Completely Changing the Way We Treat Diabetes

An estimated 347 million people worldwide -- more than the population of the United States -- currently suffer from diabetes. Currently, 25.8 million of those people live in America, accounting for 8.2% of the total population. According to the CDC, that alarming figure will rise to one in three Americans by 2050, due to poor health habits and a rapidly aging population.

However, four companies -- Novo Nordisk (NYSE: NVO  ) , Eli Lilly (NYSE: LLY  ) , MannKind (NASDAQ: MNKD  ) , and Medtronic (NYSE: MDT  ) -- are changing how diabetes is treated, and could help diabetes patients enjoy a higher quality of life than ever before.

Novo and Lilly, the pioneers of insulin
To fully appreciate how far we've come in insulin development, we need to first take a trip back in time. Prior to 1921, diabetes was considered a death sentence -- the only effective treatment was to put patients on strict diets with limited carbohydrates, which could only increase survival by a few years.

In 1921, Frederick Banting, a surgeon, succeeded in extracting insulin from a dog's pancreas. Over the next few decades, companies like Eli Lilly and Novo Nordisk started removing insulin from pigs and cattle for commercial production -- a method that improved the lives of many patients, but also caused allergic reactions.

This led to Lilly's breakthrough approval of the first genetically engineered "human" insulin, Humulin, which was produced using E. coli bacteria in 1982.

For many years, human insulin was regarded as the standard of care for diabetes patients. However, Lilly and Novo further improved insulins in the 1990s by creating insulin analogs; modifying the amino acids within the insulin make them longer acting, faster acting, or both. This advance dramatically improved the versatility of insulin -- for example, a longer-acting insulin analog could reduce the number of necessary daily injections, while a faster-acting one would be ideal after meals.

In recent years, Novo Nordisk has gone a step beyond insulin with Victoza, a new drug known as a GLP-1 analog, which stimulates the pancreas to naturally produce more insulin. Since its European approval in 2009, and FDA approval in 2010, Victoza has become one of Novo's top-selling products, accounting for 14% of its revenue last quarter.

Victoza is the current market leader in GLP-1 drugs, with a 70% market share, but other competitors such as Bristol-Myers Squibb and AstraZeneca's Byetta/Bydureon, and Sanofi's Lyxumia, are gaining ground. Lilly also has a GLP-1 drug in phase 3 trials.

MannKind's inhalable insulin
Despite all of Novo and Lilly's advances, however, all of their treatments are injected. MannKind wants to change the status quo by bringing inhalable insulin to the market.

MannKind isn't the first company to dream of replacing needles with inhalers. In 2006, Pfizer (NYSE: PFE  ) launched the first inhalable insulin, Exubera, but it was discontinued only a year later, causing a $2.8 billion writedown for the company.

Exubera failed for three main reasons -- its inhalation device was bulky (the size of a can of tennis balls), it used a confusing system of nonlinear doses, and it cost $5 per day compared to $3 for traditional insulin. In addition, needles for insulin injections have become much smaller over the years, and many diabetes patients had already grown accustomed to self-injections.

Exubera's failure was so disastrous that other inhalable insulin products from Aradigm/Novo Nordisk and Alkermes/Eli Lilly were abandoned. Yet, MannKind is still convinced that its inhalable insulin product, Afrezza, will eventually be a game changer, although it has already been rejected twice by the FDA.

Afrezza appears to be a vastly superior product to Exubera, because its inhaler is much smaller (the size of an asthma inhaler), it uses linear doses, and it uses an insulin analog, compared to Exubera's human insulin. Since Afrezza uses an insulin analog, it has a much faster peak absorption time (12-14 minutes) than either injected human insulin (60-240 minutes), or Exubera (30-90 minutes ).

Last month, MannKind resubmitted its NDA (new drug application) for Afrezza to the FDA, stating that two phase 3 studies had shown positive results. Investors are definitely hoping that the third time's the charm for MannKind -- a volatile stock that has slid more than 20% during the past six months. If approved, Afrezza could generate annual peak sales of $2 billion, and possibly render injected insulin from Novo, Lilly, and Sanofi obsolete.

Medtronic creates the first wearable artificial pancreas
Last but not least, we should also take a look at Medtronic, the largest medical-device maker in the world. Medtronic has extended human lives by mechanical means ever since it created the world's first battery powered external pacemaker in 1957. Since then, Medtronic's pacemakers have helped patients with heart conditions live longer than ever.

Last month, the FDA approved the MiniMed 530, the first wearable artificial pancreas in the world for patients with type 1 diabetes. Type 1 diabetes patients cannot naturally produce any insulin, and must use continuous pin pricks and insulin injections throughout the day to carefully control their blood glucose levels.

The MiniMed 530 is a combination of a wearable glucose meter and an insulin pump. The pump injects insulin until the glucose meter detects that blood sugar levels have fallen below a defined threshold. This level of automation had never been seen before -- other similar products like Insulet's OnmiPod require patients to manually operate the pump.

Although it's not a perfectly closed loop system, the MiniMed 530 is a huge step forward in improving the daily lives of type 1 diabetes patients. Medtronic's device has attracted a lot of attention -- Johnson & Johnson and Dexcom are also working together on a competing artificial pancreas known as Animas.

The Foolish takeaway
It's amazing how much progress has been made in diabetes treatments during the last 92 years. From extracting insulin from dogs, companies have synthesized human insulin, drugs that stimulate the pancreas to produce insulin, and even wearable machines that can replace the pancreas altogether.

It will be exciting to see what incredible new ways these four companies, along with many others, can improve the lives of diabetes patients over the next few decades.

Understanding Obamacare
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called Everything You Need to Know About Obamacare. But don't hesitate; because it's not often that we release a FREE guide containing this much information and money-making advice. Please click here to access your free copy.


Read/Post Comments (4) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 29, 2013, at 5:13 PM, smurf74 wrote:

    Very interesting but how affordable would an inhaled insulin be? Many of us live paycheck,to nothing at all and insulin is very expensive. Let alone having to check sugar levels up to 5-6 times a day and more when someone is sick. I hope everything turns out for the best interest of the patients such as myself.

  • Report this Comment On November 30, 2013, at 1:07 AM, TMFSunLion wrote:

    Thanks for reading. The final price of Afrezza is currently unknown, and will only be known after market approval.

    However, I believe that MannKind is aiming for a price equivalent to or near the price of injected insulin -- since pricing was one of Pfizer's big mistakes with Exubera.

  • Report this Comment On November 30, 2013, at 9:17 AM, p716 wrote:

    Lily only commercialized recombinant insulin. They licensed the process from Herb Boyer, founder of Genentech.

  • Report this Comment On December 02, 2013, at 2:03 AM, bamobrien wrote:

    I think its worth bringing up that Exubera produced an increased risk of respiratory infections especially in pediatric patients. A risk that isn't present for Afrezza.

Add your comment.

DocumentId: 2746359, ~/Articles/ArticleHandler.aspx, 4/17/2014 7:08:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement